non nmda receptor antagonist 6 7 dinitroquinoxaline 2 3 dione  (Tocris)

Journal: Journal of Neuroinflammation

Article Title: Inflammatory demyelination alters subcortical visual circuits

doi: 10.1186/s12974-017-0936-0

Figure Lengend Snippet: Cuprizone treatment (5 weeks) leads to a decrease in retinogeniculate network activity. a Representative example of traces obtained in the presence (red; iGluR blockade) or absence (black; baseline) of the glutamate receptor antagonists APV (NMDA receptor-selective) and DNQX (AMPA/kainate receptor-selective). Note that only the second peak of the traces is glutamate receptor inhibition-sensitive. b , c Representative example ( b ) and bar graph depicting the current amplitude ( c ) of traces obtained in the presence (red; GluN2B blockade) or absence (black; baseline) of Ro 25-6981, a selective blocker of NMDA receptors containing the GluN2B subunit. n = 5: cuprizone; n = 8: control. The bar graph depicts means ± SEMs. * p < 0.05, ** p < 0.01, *** p < 0.001, not significant (ns) p ≥ 0.05 (unpaired two-tailed Student’s t test)

Article Snippet: In each slice, the peak amplitude of the synaptic-dependent field negativity post-drug was normalized using pre-drug values, whereby the second of two evoked negative field potential peaks was identified as the synaptic-dependent field potential by comparing recordings in normal aCSF to those in aCSF containing the competitive NMDA receptor antagonist APV (50 μM, Tocris Bioscience) and the competitive non-NMDA glutamate receptor antagonist DNQX (20 μM, Tocris Bioscience).

Techniques: Activity Assay, Inhibition, Control, Two Tailed Test